



The Ohio State University

University Hospitals  
410 West 10th Avenue  
Columbus, Ohio 43210

366

DOCKET NUMBER  
PETITION RULE PRM 35-9  
(54 FR 38239)

'89 DEC 11 P2:31

December 5, 1989

OFFICE OF THE  
DOCKETING AND SERVICE  
BRANCH

Secretary of the Commission  
United State Nuclear Regulatory Commission  
Docketing and Service Branch, Docket # PRM-35-9  
Washington, D.C. 20555

Dear Mr. Secretary:

I am writing to express my strong support for the Petition for Rulemaking filed by the American College of Nuclear Physicians and the Society of Nuclear Medicine. I am a practicing nuclear pharmacist at The Ohio State University Medical Center. I am deeply concerned over the revised 10 CFR 35 regulations governing the medical use of byproduct material as they significantly impact my ability to practice high-quality nuclear pharmacy as requested by the physicians working in this medical facility and are preventing me from providing optimized care to individual patients.

For example, according to the regulations I would be forced to strictly follow the manufacturers' instructions for kit preparation and expiration times. Often a physician may request the preparation be slightly modified to provide better care to a particular patient. I feel this is restricting the practice of medicine that is the medical judgement to be made by the physician. In the practice of medicine, I feel the physician should have the ability to choose within reason how the drug is prepared, the route of administration, radioactivity levels and indications.

The NRC should recognize that the FDA does allow, and often encourages, other clinical uses of approved drugs, and actively discourages the submission of physician-sponsored IND's that describe new indications for approved drugs. The package insert was never intended to prohibit physicians from deviating from it for other indications; on the contrary, such deviation is necessary for growth in developing new diagnostic and therapeutic procedures. In many cases, manufacturers will never go back to the FDA to revise a package insert to include a new indication because it is not required by the FDA and there is simply no economic incentive to do so.

Currently, the regulatory provisions in Part 35[35.100, 35.200, 35.300, and 35.17(a)(4)] do not allow practices which are legitimate and legal under FDA regulations and State medicine and pharmacy laws. These regulations therefore inappropriately interfere with the practice of medicine, which directly contradicts the NRC's Medical Policy statement against such interference.

8912180078 891205  
PDR PRM  
35-9

PDR  
Dodd Hall / Means Hall / Rhodes Hall University Hospital / Starling Loving Hall /  
University Hospitals Clinic / Upham Hall / Wiseman Hall

DS/0

Secretary of the Commission  
December 5, 1989  
page 2

Finally, I would like to point out that highly restrictive NRC regulations will only jeopardize public health and safety by: restricting access to appropriate nuclear medicine procedures; exposing patients to higher radiation absorbed doses from alternative legal, but non-optimal, studies; and exposing hospital personnel to higher radiation absorbed doses because of unwarranted, repetitive procedures. The NRC should not strive to construct proscriptive regulations to cover all aspects of medicine, nor should it attempt to regulate radiopharmaceutical use. Instead, the NRC should rely on the expertise of the FDA, State Boards of Pharmacy, State Boards of Medical Quality Assurance, the Joint Commission on Accreditation of Healthcare Organizations, radiation safety committees, institutional quality assurance review procedures and most importantly, the professional judgement of pharmacists and physicians who have been well-trained to prepare and administer these materials.

Since the NRC's primary regulatory focus appear to be based on the unsubstantiated assumption that misadministrations, particularly those involving diagnostic radiopharmaceuticals, pose a serious threat to the public health and safety, I strongly urge the NRC to pursue a comprehensive study by a reputable scientific panel, such as the National Academy of Sciences or the National Council on Radiation Protection, to assess the radiobiological effects of misadministrations from nuclear medicine diagnostic and therapeutic procedures. I firmly believe the results of such a study will demonstrate that the NRC's efforts to impose more and more stringent regulations are unnecessary and not cost-effective in relation to the extremely low health risks of these studies.

In closing, I strongly urge the NRC to adopt the American College of Nuclear Physicians/Society of Nuclear Medicine Petition for Rulemaking as expeditiously as possible.

Sincerely,

*Steve R. Lefevre, R.Ph.*

Steve R. Lefevre, R.Ph., BCNP  
Nuclear Pharmacy Services  
The Ohio State University Medical Center  
Room N-162, Doan Hall  
410 West Tenth Avenue  
Columbus, OHIO 43210